![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Axsome Therapeutics’ Investigational Narcolepsy Drug Gets Breakthrough Therapy Designation
Axsome Therapeutics’ Investigational Narcolepsy Drug Gets Breakthrough Therapy Designation
Axsome Therapeutics has earned a Breakthrough Therapy designation from the FDA for AXS-12 (reboxetine) for the treatment of cataplexy, a sudden loss of voluntary muscle tone, in patients with narcolepsy.
The designation was based on the results of a phase 2 trial in which AXS-12 reduced the number of cataplexy attacks compared to a placebo over a two-week treatment period.
The FDA granted AXS-12 an Orphan Drug designation in 2018 for the treatment of narcolepsy.
Upcoming Events
-
21Oct